The stock for GILD is currently valued at $121.08, reflecting an approximate increase of 2.23%. Today, the stock has ascended by $2.64, trading between a low of $114.02 and a high of $121.91. Over the past year, GILD has experienced a peak of $124.61 and a trough of $86.08, showcasing notable stock price volatility. With a market capitalization of roughly $150.24 billion, Gilead solidifies its significant stature within the biopharmaceutical sector. The trading volume for GILD today stands at 3,555,932 shar ...

EARNINGS PREVIEW: Palantir, Robinhood Among Leaders Set To ReportGilead stock reversed its losses early Friday as analysts noted encouraging indicators for its newly approved HIV prevention shot.Yeztugo is a twice-annual injection that aims to prevent HIV infection from taking hold in at-risk people. During the third quarter, it generated $39 million in sales, RBC Capital Markets analyst Brian Abrahams said in a report. He acknowledged that while sales beat sell-side expectations for $35 million, the buy-si ...

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh. ...

Gilead Sciences (GILD) came out with quarterly earnings of $2.47 per share, beating the Zacks Consensus Estimate of $2.15 per share. This compares to earnings of $2.02 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of +14.88%. A quarter ago, it was expected that this HIV and hepatitis C drugmaker would post earnings of $1.95 per share when it actually produced earnings of $2.01, delivering a surprise of +3.08%.Over the last four ...

Gilead Sciences (NasdaqGS:GILD) Q3 2025 Earnings Call October 30, 2025 04:30 PM ET Speaker0Good afternoon, everyone, and welcome to Gilead's Third Quarter twenty twenty five Earnings Conference Call. My name is Rebecca, and I'll be today's host. In a moment, we'll begin our prepared remarks followed by our Q and A session. Now I'll hand the call over to Jackie Ross, Senior Vice President of Treasury and Investor Relations.Speaker1Thank you, Rebecca. Just after market closed today, we issued a press release ...

Q325 Financial Results 1 0 D e c e m b e r 2 0 2 4 O c t o b e r 3 0 , 2 0 2 5 Forward-Looking Statements Statements included in this document that are not historical in nature are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Gilead cautions readers that forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially. These risks and uncertainties include those relating to: Gilead's abili ...

Gilead Sciences said on Thursday its HIV drug sales rose 4% to $5.3 billion in the third quarter including $39 million for its new prevention drug Yeztugo, helping to boost its profit above Wall Stree... ...

Foster City, CA, October 30, 2025 - Gilead Sciences, Inc. (Nasdaq: GILD) announced today its third quarter 2025 results of operations. "We continue to deliver on Gilead's robust portfolio with a strong start for Yeztugo, rapidly growing uptake of Biktarvy, Descovy and Livdelzi, and positive data for Trodelvy in 1L metastatic triple negative breast cancer," said Daniel O'Day, Gilead's Chairman and Chief Executive Officer. "With multiple potential product launches in 2026, the strongest clinical pipeline in G ...

Key Takeaways Gilead will report Q3 2025 results on Oct. 30, with sales and EPS estimates of $7.46B and $2.15.HIV portfolio strength from Biktarvy, Descovy, and new approval Yeztugo is driving top-line growth.Cell Therapy sales likely declined amid competition, while Trodelvy and Livdelzi demand stayed strong.Biotech bigwig Gilead Sciences, Inc. (GILD)   is scheduled to report third-quarter 2025 results on Oct. 30, after market close. The Zacks Consensus Estimate for sales and earnings is pegged at $7.46 bi ...

美国食品和药物管理局（FDA）今年已批准来那卡帕韦用于艾滋病预防。吉利德公司此前接受《纽约时 报》采访时透露，该药在美国市场的标价为每人每年2.8万美元。 责编：张青津、姚凯红 新华社约翰内斯堡10月28日电（记者白舸 蒋国鹏）南非医疗卫生产品管理局27日宣布，正式批准新型 抗艾药物来那卡帕韦在南非注册使用。这标志着南非成为非洲首个批准这款长效注射剂的国家。 这款由美国吉利德科技公司研发的长效注射药物每年仅需注射两次，每次注射可提供长达6个月的免疫 保护，将有效降低艾滋病病毒感染风险。这种药物通过靶向艾滋病病毒的衣壳蛋白起效，能够干扰艾滋 病病毒衣壳蛋白侵入细胞核，阻止病毒复制，还能干扰病毒的组装和成熟过程。 南非卫生部长阿伦·莫措阿莱迪说，这一药物填补了现有艾滋病预防手段的关键短板，政府计划于2026 年3月正式推出该药。通过与吉利德等7家药企达成协议，该药的年治疗费将大幅降低。 南非医疗卫生产品管理局首席执行官博伊图梅洛·塞梅特-马科科特莱拉说，来那卡帕韦是迄今最有效的 艾滋病预防药物，在艾滋病病毒感染率高的南非，其注册具有颠覆性意义。 ...